David C Montefiori1, Lynn Morris, Guido Ferrari, John R Mascola. 1. aDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, USA bNational Institute for Communicable Diseases, Johannesburg, South Africa cVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: New findings continue to support the notion that broadly crossreactive neutralizing antibody induction is a worthwhile and achievable goal for HIV-1 vaccines. Immunogens are needed that can overcome the genetic variability and complex immune evasion tactics of the virus. Other antibodies might bridge innate and acquired immunity for possible beneficial vaccine effects. This review summarizes progress made over the past year that has enhanced our understanding of humoral immunity as it relates to HIV-1 vaccine development. RECENT FINDINGS: Although a clear path to designing an effective neutralizing antibody-based HIV-1 vaccine remains elusive, there is new information on how antibodies neutralize HIV-1, the epitopes involved, and clues to the possible nature of protective immunogens that keep this goal alive. Moreover, there is a greater understanding of HIV-1 diversity and its possible limits under immune pressure. Other antibodies might possess antiviral activity by mechanisms involving Fc receptor engagement or complement activation that would be of value for HIV-1 vaccines. SUMMARY: Recent developments strengthen the rationale for antibody-based HIV-1 vaccine immunogens and provide a stronger foundation for vaccine discovery.
PURPOSE OF REVIEW: New findings continue to support the notion that broadly crossreactive neutralizing antibody induction is a worthwhile and achievable goal for HIV-1 vaccines. Immunogens are needed that can overcome the genetic variability and complex immune evasion tactics of the virus. Other antibodies might bridge innate and acquired immunity for possible beneficial vaccine effects. This review summarizes progress made over the past year that has enhanced our understanding of humoral immunity as it relates to HIV-1 vaccine development. RECENT FINDINGS: Although a clear path to designing an effective neutralizing antibody-based HIV-1 vaccine remains elusive, there is new information on how antibodies neutralize HIV-1, the epitopes involved, and clues to the possible nature of protective immunogens that keep this goal alive. Moreover, there is a greater understanding of HIV-1 diversity and its possible limits under immune pressure. Other antibodies might possess antiviral activity by mechanisms involving Fc receptor engagement or complement activation that would be of value for HIV-1 vaccines. SUMMARY: Recent developments strengthen the rationale for antibody-based HIV-1 vaccine immunogens and provide a stronger foundation for vaccine discovery.
Authors: John R Mascola; Patricia D'Souza; Peter Gilbert; Beatrice H Hahn; Nancy L Haigwood; Lynn Morris; Christos J Petropoulos; Victoria R Polonis; Marcella Sarzotti; David C Montefiori Journal: J Virol Date: 2005-08 Impact factor: 5.103
Authors: Emma T Crooks; Penny L Moore; Douglas Richman; James Robinson; Jeffrey A Crooks; Michael Franti; Norbert Schülke; James M Binley Journal: Hum Antibodies Date: 2005
Authors: Bing Li; Julie M Decker; Roy W Johnson; Frederic Bibollet-Ruche; Xiping Wei; Joseph Mulenga; Susan Allen; Eric Hunter; Beatrice H Hahn; George M Shaw; Jerry L Blackwell; Cynthia A Derdeyn Journal: J Virol Date: 2006-06 Impact factor: 5.103
Authors: Fatim Cham; Peng Fei Zhang; Leo Heyndrickx; Peter Bouma; Ping Zhong; Herman Katinger; James Robinson; Guido van der Groen; Gerald V Quinnan Journal: Virology Date: 2005-12-27 Impact factor: 3.616
Authors: Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori Journal: J Virol Date: 2005-08 Impact factor: 5.103
Authors: Vidita Choudhry; Mei-Yun Zhang; Ilia Harris; Igor A Sidorov; Bang Vu; Antony S Dimitrov; Timothy Fouts; Dimiter S Dimitrov Journal: Biochem Biophys Res Commun Date: 2006-08-04 Impact factor: 3.575
Authors: Ying Lian; Indresh Srivastava; V Rául Gómez-Román; Jan Zur Megede; Yide Sun; Elaine Kan; Susan Hilt; Susan Engelbrecht; Sunee Himathongkham; Paul A Luciw; Gillis Otten; Jeffrey B Ulmer; John J Donnelly; Dietmar Rabussay; David Montefiori; Estrelita Janse van Rensburg; Susan W Barnett Journal: J Virol Date: 2005-11 Impact factor: 5.103
Authors: Julie M Decker; Frederic Bibollet-Ruche; Xiping Wei; Shuyi Wang; David N Levy; Wenquan Wang; Eric Delaporte; Martine Peeters; Cynthia A Derdeyn; Susan Allen; Eric Hunter; Michael S Saag; James A Hoxie; Beatrice H Hahn; Peter D Kwong; James E Robinson; George M Shaw Journal: J Exp Med Date: 2005-05-02 Impact factor: 14.307
Authors: Anthony R Geonnotti; Miroslawa Bilska; Xing Yuan; Christina Ochsenbauer; Tara G Edmonds; John C Kappes; Hua-Xin Liao; Barton F Haynes; David C Montefiori Journal: AIDS Res Hum Retroviruses Date: 2010-03 Impact factor: 2.205
Authors: Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola Journal: Science Date: 2010-07-08 Impact factor: 47.728
Authors: Guohua Yi; Mauro Lapelosa; Rachel Bradley; Thomas M Mariano; Denise Elsasser Dietz; Scott Hughes; Terri Wrin; Chris Petropoulos; Emilio Gallicchio; Ronald M Levy; Eddy Arnold; Gail Ferstandig Arnold Journal: PLoS One Date: 2013-09-06 Impact factor: 3.240